Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2026
Key Highlights
- ➤Pevifoscorvir sodium reduced pro-inflammatory cytokine expression after 96 weeks of monotherapy
- ➤ALG-001075 inhibited HBV rcDNA and dslDNA formation across multiple cell models
- ➤ALG-170675 achieved deeper HBsAg knockdown than bepirovirsen in an AAV-HBV mouse model
- ➤ALG-215007 potently inhibited hepatitis delta virus replication across multiple cellular systems
- ➤ALG-170675 is progressing through a Phase 1 study in China with partner Amoytop
Expert Statements
Lawrence Blatt, Chairman, President, and Chief Executive Officer of Aligos Therapeutics
“The data the team will present at The Liver Meeting® underscores the strength of our pipeline”
Lawrence Blatt, Chairman, President, and Chief Executive Officer of Aligos Therapeutics
“The pevifoscorvir sodium findings provide important new insights into the potential of a potent CAM-E compound to reduce pro-inflammatory cytokines which have been linked to disease progression in chronic HBV infection and inhibit viral HBV DNA forms associated with integration”
Lawrence Blatt, Chairman, President, and Chief Executive Officer of Aligos Therapeutics
“The preclinical profile of ALG-170675, our potentially best-in-class HBV antisense oligonucleotide, which is currently progressing through a Phase 1 study in China with our partner Amoytop, further supports the promise of our next-generation approaches in chronic HBV infection”
Lawrence Blatt, Chairman, President, and Chief Executive Officer of Aligos Therapeutics
“Together, these data reinforce our strategy of applying deep scientific expertise to develop potentially best-in-class therapies that can meaningfully improve patient outcomes.”
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from five presentations at the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting® 2026, being held November 5 – 9, 2026 in Denver, CO.
“The data the team will present at The Liver Meeting® underscores the strength of our pipeline,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “The pevifoscorvir sodium findings provide important new insights into the potential of a potent CAM-E compound to reduce pro-inflammatory cytokines which have been linked to disease progression in chronic HBV infection and inhibit viral HBV DNA forms associated with integration. The preclinical profile of ALG-170675, our potentially best-in-class HBV antisense oligonucleotide, which is currently progressing through a Phase 1 study in China with our partner Amoytop, further supports the promise of our next-generation approaches in chronic HBV infection. Together, these data reinforce our strategy of applying deep scientific expertise to develop potentially best-in-class therapies that can meaningfully improve patient outcomes.”
Get started
Create a free account to read the full story.